Cargando…

Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide

BACKGROUND: Human CD1d-restricted, invariant natural killer T cells (iNKT) are a unique class of T lymphocytes that recognise glycolipid antigens such as α-galactosylceramide (αGalCer) and upon T cell receptor (TCR) activation produce both Th1 and Th2 cytokines. iNKT cells expand when cultured in-vi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Croudace, Joanne E, Curbishley, Stuart M, Mura, Manuela, Willcox, Carrie R, Illarionov, Petr A, Besra, Gurdyal S, Adams, David H, Lammas, David A
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613383/ https://www.ncbi.nlm.nih.gov/pubmed/19055753 http://dx.doi.org/10.1186/1471-2172-9-71

Ejemplares similares

Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15
por: Hsu, Chien-Ya, et al.
Publicado: (2021)

Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases
por: Gadola, Stephan D., et al.
Publicado: (2006)

α-Galactosylceramide Analogs with Weak Agonist Activity for Human iNKT Cells Define New Candidate Anti-Inflammatory Agents
por: Bricard, Gabriel, et al.
Publicado: (2010)

Exogenous Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Reduces Pneumococcal Outgrowth and Dissemination Postinfluenza
por: Barthelemy, Adeline, et al.
Publicado: (2016)

CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

ATP-induced autophagy is associated with rapid killing of intracellular mycobacteria within human monocytes/macrophages
por: Biswas, Debasis, et al.
Publicado: (2008)

Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses
por: Zhang, Lianjun, et al.
Publicado: (2017)

A humanized mouse model for in vivo evaluation of invariant Natural Killer T cell responses
por: Saavedra-Avila, Noemi Alejandra, et al.
Publicado: (2022)

α-galactosylceramide-stimulated invariant natural killer T-cells play a protective role in murine vulvovaginal candidiasis by Candida albicans
por: Abe, Masahiro, et al.
Publicado: (2021)

Activation of invariant natural killer T cells stimulated with microbial α-mannosyl glycolipids
por: Shimamura, Michio, et al.
Publicado: (2017)

Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Attenuates the Development of Angiotensin II-Mediated Abdominal Aortic Aneurysm in Obese ob/ob Mice
por: Saito, Akimichi, et al.
Publicado: (2021)

Invariant natural killer T cells recognize lipid self-antigen induced by microbial danger signals
por: Brennan, Patrick J., et al.
Publicado: (2011)

Direct cell-to-cell spread of a pathogenic yeast
por: Ma, Hansong, et al.
Publicado: (2007)

Natural Killer Dendritic Cells Enhance Immune Responses Elicited by α-Galactosylceramide-Stimulated Natural Killer T Cells
por: Lee, Sung Won, et al.
Publicado: (2013)

Repeated administration of alpha-galactosylceramide ameliorates experimental lupus nephritis in mice
por: Uchida, Takahiro, et al.
Publicado: (2018)

Sterile activation of invariant natural killer T cells by ER-stressed antigen-presenting cells
por: Bedard, Melissa, et al.
Publicado: (2019)

Natural Killer T Cell Ligand α-Galactosylceramide Enhances Protective Immunity Induced by Malaria Vaccines
por: Gonzalez-Aseguinolaza, Gloria, et al.
Publicado: (2002)

α‐galactosylceramide generates lung regulatory T cells through the activated natural killer T cells in mice
por: Chen, Qianhui, et al.
Publicado: (2018)

Alpha-galactosylceramide enhances mucosal immunity to oral whole-cell cholera vaccines
por: Davitt, Christopher J. H., et al.
Publicado: (2019)

α‐Galactosylceramide‐activated murine NK1.1(+) invariant‐NKT cells in the myometrium induce miscarriages in mice
por: Ichikawa, Tomoko, et al.
Publicado: (2016)

Natural Killer T Cell Ligand α‐Galactosylceramide Inhibited Lymph Node Metastasis of Highly Metastatic Melanoma Cells
por: Nakui, Minoru, et al.
Publicado: (1999)

PPARγ controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells
por: Szatmari, Istvan, et al.
Publicado: (2006)

Enhancement of Mucosal Immunogenicity of Viral Vectored Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant
por: Singh, Shailbala, et al.
Publicado: (2014)

Kinetics and Cellular Site of Glycolipid Loading Control the Outcome of Natural Killer T Cell Activation
por: Im, Jin S., et al.
Publicado: (2009)

Lipoproteins act as vehicles for lipid antigen delivery and activation of invariant natural killer T cells
por: Engelen, Suzanne E., et al.
Publicado: (2023)

In vitro anti-tumour activity of α-galactosylceramide-stimulated human invariant Vα24+NKT cells against melanoma
por: Kikuchi, A, et al.
Publicado: (2001)

Activation of Invariant NKT Cells with Glycolipid Ligand α-Galactosylceramide Ameliorates Glucose-6-Phosphate Isomerase Peptide-Induced Arthritis
por: Horikoshi, Masanobu, et al.
Publicado: (2012)

CD1d-mediated Recognition of an α-Galactosylceramide by Natural Killer T Cells Is Highly Conserved through Mammalian Evolution
por: Brossay, Laurent, et al.
Publicado: (1998)

Toll-like Receptor agonists and alpha-galactosylceramide synergistically enhance the production of interferon-gamma in murine splenocytes
por: Ando, Tatsuya, et al.
Publicado: (2013)

A Subset of Liver NK T Cells Is Activated during Leishmania donovani Infection by CD1d-bound Lipophosphoglycan
por: Amprey, Joseph L., et al.
Publicado: (2004)

Invariant NKT cells recognize glycolipids from pathogenic Gram-positive bacteria
por: Kinjo, Yuki, et al.
Publicado: (2011)

Superior Protection against Malaria and Melanoma Metastases by a C-glycoside Analogue of the Natural Killer T Cell Ligand α-Galactosylceramide
por: Schmieg, John, et al.
Publicado: (2003)

CD169(+) MACROPHAGES PRESENT LIPID ANTIGENS TO MEDIATE EARLY ACTIVATION OF INVARIANT NKT CELLS IN LYMPH NODES
por: Barral, Patricia, et al.
Publicado: (2010)

Distinct Bioenergetic Features of Human Invariant Natural Killer T Cells Enable Retained Functions in Nutrient-Deprived States
por: Khurana, Priya, et al.
Publicado: (2021)

Prophylactic Sublingual Immunization with Mycobacterium tuberculosis Subunit Vaccine Incorporating the Natural Killer T Cell Agonist Alpha-Galactosylceramide Enhances Protective Immunity to Limit Pulmonary and Extra-Pulmonary Bacterial Burden in Mice
por: Khan, Arshad, et al.
Publicado: (2017)

Inhibition of iNOS activity enhances the anti-tumor effects of alpha-galactosylceramide in established murine cancer model
por: Ito, Hiroyasu, et al.
Publicado: (2015)

Alpha-galactosylceramide enhances protective immunity induced by DNA vaccine of the SAG5D gene of Toxoplasma gondii
por: Lu, Gang, et al.
Publicado: (2014)

Invariant Natural Killer T and Mucosal-Associated Invariant T Cells in Asthmatic Patients
por: Lezmi, Guillaume, et al.
Publicado: (2018)

Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer
por: Wang, Ying, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_82fpe85k6i3u7sim4cvdop015h